• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Takeda Pharmaceutical Company Limited (Amendment)

    2/5/24 6:24:58 AM ET
    $TAK
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $TAK alert in real time by email
    SC 13G/A 1 tak131246sc13ga3.htm AMENDMENT NO. 3

     

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION 

    Washington, D.C. 20549

     ________________ 

      

    SCHEDULE 13G/A

     

    Under the Securities Exchange Act of 1934

     

    (Amendment No. 3)*

     

     

    Takeda Pharmaceutical Company Limited
    (Name of Issuer)
     
    Common Stock
    (Title of Class of Securities)
     
    874060205
    (CUSIP Number)
     
    December 31, 2023
    (Date of Event which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ☒       Rule 13d-1(b)

     

    ☐       Rule 13d-1(c)

     

    ☐       Rule 13d-1(d)

     

    _____________________________

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     Page 1 of 6 
     

     

    CUSIP No. 874060205                 13G/A  

     

    1.

    NAMES OF REPORTING PERSONS

     

    Sumitomo Mitsui Trust Holdings, Inc.

      

    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a)    ☐
       

    (b)    ☐

     

    3.

    SEC USE ONLY

     

    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Japan

     

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5.

    SOLE VOTING POWER

    0

     

    6.

    SHARED VOTING POWER

    79,074,334

     

    7.

    SOLE DISPOSITIVE POWER

    0

     

    8.

    SHARED DISPOSITIVE POWER

    87,400,834

     

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    87,400,834

     

    10.

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions)

     

    ☐

    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    5.5%

    12.

    TYPE OF REPORTING PERSON (see instructions)

     

    HC, FI

     

     Page 2 of 6 
     

     

     Item 1(a). Name of Issuer:

     

    Takeda Pharmaceutical Company Limited

     

    Item 1(b). Address of Issuer’s Principal Executive Offices:

     

    1-1, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo 103-8668, Japan

     

    Item 2(a). Name of Person Filing:

     

    Sumitomo Mitsui Trust Holdings, Inc.

     

    Item 2(b). Address of Principal Business Office or, if None, Residence:

     

    1-4-1 Marunouchi, Chiyoda-ku, Tokyo 100-8233, Japan

     

    Item 2(c). Citizenship:

     

    Japan

     

    Item 2(d). Title of Class of Securities:

     

    Common Stock

     

    Item 2(e). CUSIP Number:

     

    874060205

     

    Item 3.If this Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a:

     

    (a) ☐  Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o);
         
    (b) ☐  Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c);
         
    (c) ☐  Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c);
         
    (d) ☐  Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
         
    (e) ☐  An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
         
    (f) ☐  An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
         
    (g) ☒  A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
         
    (h) ☐  A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
         
    (i) ☐  A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
         
    (j) ☒  A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);
         
    (k) ☐  Group, in accordance with §240.13d-1(b)(1)(ii)(K).

     

    If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution: Parent Holding Company

     

     Page 3 of 6 
     

     

    Item 4.Ownership.

     

    Provide the following information regarding the aggregate number and percentage of the class of securities of issuer identified in Item 1.

     

    (a)   Amount beneficially owned: 87,400,834
         
    (b)   Percent of class: 5.5%
         
    (c)   Number of shares as to which such person has:
         
    (i)   Sole power to vote or to direct the vote: 0
         
    (ii)   Shared power to vote or to direct the vote: 79,074,334
         
    (iii)   Sole power to dispose or to direct the disposition of: 0
         
    (iv)   Shared power to dispose or to direct the disposition of: 87,400,834

     

    Item 5.Ownership of Five Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following. ☐

     

    Item 6.Ownership of More than Five Percent on Behalf of Another Person.

     

    Not applicable.

     

    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.

     

    See Exhibit A.

     

    Item 8.Identification and Classification of Members of the Group.

     

    Not applicable.

     

    Item 9.Notice of Dissolution of Group.

     

    Not applicable.

     

    Item 10.Certifications.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     Page 4 of 6 
     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date: February 5, 2024

     

      Sumitomo Mitsui Trust Holdings, Inc.
      (Company)
       
      /s/ Hideaki Takamiya
     

    (Signature)

     

    Hideaki Takamiya / Senior Manager of Risk
    Management Dept 

      (Name/Title)

     

     Page 5 of 6 
     

     

    Exhibit A

    Pursuant to the instructions in Item 7 of Schedule 13G, portions of the securities being reported on by Sumitomo Mitsui Trust Holdings, Inc. as a parent holding company are owned, or may be deemed to be beneficially owned, by its subsidiaries: each of (a) Sumitomo Mitsui Trust Asset Management Co., Ltd. and (b) Nikko Asset Management Co., Ltd. is classified as an investment adviser in accordance with §240.13d-1(b)(1)(ii)(E) and as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J).

     

     

    Page 6 of 6

     

     

     

    Get the next $TAK alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $TAK

    DatePrice TargetRatingAnalyst
    4/2/2025Equal-Weight → Overweight
    Morgan Stanley
    3/16/2023$20.00Neutral → Buy
    BofA Securities
    7/19/2022$21.00 → $24.00Market Perform → Outperform
    Cowen
    10/7/2021Overweight → Equal-Weight
    Morgan Stanley
    More analyst ratings

    $TAK
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Takeda Announces FY2024 Full Year Results and FY2025 Outlook Reflecting Growth & Launch Products Momentum, Strong Cash Flow Generation and Late-Stage Pipeline Progress

      Core Revenue Growth of 7.4% at Actual Exchange Rates (AER), + 2.8% at Constant Exchange Rate (CER) in FY2024 Core Operating Profit Growth of 4.9% at CER with Efficiency Program Driving Cost Savings Up to Six New Molecular Entities in Phase 3 Development in FY2025 with Three Phase 3 Data Readouts Recently Completed or Anticipated FY2025 Outlook for Broadly Flat Revenue and Core Profit Reflecting Product Momentum and Increasing Investment in New Launch Preparation Proposed Dividend Increase from JPY 196 to JPY 200 Takeda ((4502, NYSE:TAK) today announced financial results for fiscal year 2024 (period ended March 31, 2025) with continued strong momentum in Growth & Launch Products o

      5/8/25 2:36:00 AM ET
      $TAK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BioLife Plasma Services Introduces the New Fresenius Kabi Adaptive Nomogram Across its U.S. Network of Plasma Donation Centers

      -New Technology Optimizes Plasma Collection Resulting in Efficiency Gains -Helps Strengthen Plasma Supply Used to Produce Lifesaving and Life-Sustaining Medicines BioLife Plasma Services, part of Takeda (NYSE:TAK), today announced that it has begun introducing the new Fresenius Kabi Adaptive Nomogram across its U.S. network of plasma donation centers. The new Adaptive Nomogram is used on the Aurora Xi Plasmapheresis System, which is in more than half of BioLife's U.S. plasma donation centers. This new technology will be running in all BioLife donation centers using the Aurora Xi Plasmapheresis System by the end of December 2025. This press release features multimedia. View the full relea

      5/5/25 8:00:00 AM ET
      $TAK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Takeda Awards $13.8 Million to U.S. Nonprofit Partners to Promote Healthy Eating and Expand STEM Education

      Annual Grants Deepen Takeda's Commitment to Improving Health Through Community-Based Programs Takeda Publishes U.S. Community Impact Report Highlighting Progress toward a More Equitable Health Ecosystem See the full release at Takeda.com View source version on businesswire.com: https://www.businesswire.com/news/home/20250430215346/en/ Media Contact: Takeda Media Relations [email protected]

      4/30/25 8:05:00 AM ET
      $TAK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TAK
    SEC Filings

    See more
    • SEC Form 6-K filed by Takeda Pharmaceutical Company Limited

      6-K - TAKEDA PHARMACEUTICAL CO LTD (0001395064) (Filer)

      5/8/25 6:19:03 AM ET
      $TAK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Takeda Pharmaceutical Company Limited

      6-K - TAKEDA PHARMACEUTICAL CO LTD (0001395064) (Filer)

      5/8/25 6:14:51 AM ET
      $TAK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Takeda Pharmaceutical Company Limited

      6-K - TAKEDA PHARMACEUTICAL CO LTD (0001395064) (Filer)

      4/22/25 6:08:45 AM ET
      $TAK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TAK
    Financials

    Live finance-specific insights

    See more
    • Takeda Announces FY2024 Full Year Results and FY2025 Outlook Reflecting Growth & Launch Products Momentum, Strong Cash Flow Generation and Late-Stage Pipeline Progress

      Core Revenue Growth of 7.4% at Actual Exchange Rates (AER), + 2.8% at Constant Exchange Rate (CER) in FY2024 Core Operating Profit Growth of 4.9% at CER with Efficiency Program Driving Cost Savings Up to Six New Molecular Entities in Phase 3 Development in FY2025 with Three Phase 3 Data Readouts Recently Completed or Anticipated FY2025 Outlook for Broadly Flat Revenue and Core Profit Reflecting Product Momentum and Increasing Investment in New Launch Preparation Proposed Dividend Increase from JPY 196 to JPY 200 Takeda ((4502, NYSE:TAK) today announced financial results for fiscal year 2024 (period ended March 31, 2025) with continued strong momentum in Growth & Launch Products o

      5/8/25 2:36:00 AM ET
      $TAK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Protagonist and Takeda Announce Positive Topline Results from Phase 3 VERIFY Study of Rusfertide in Patients with Polycythemia Vera

      − Study met the primary endpoint, with a significantly higher proportion of clinical responders on rusfertide compared to placebo − All four key secondary endpoints were met, including EU primary endpoint and patient-reported outcomes − Rusfertide was generally well tolerated; no new safety findings were observed in the study Protagonist Therapeutics, Inc. ("Protagonist") ((PTGX) and Takeda ((TAK) today announced positive topline results for the Phase 3 VERIFY study, in which phlebotomy-dependent patients with polycythemia vera (PV) were randomized to treatment with either rusfertide or placebo, as an add-on to standard of care treatment. The study met its primary endpoint and all fou

      3/3/25 6:45:00 AM ET
      $PTGX
      $TAK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Takeda Delivers Strong Third-Quarter FY2024 Results; Raises Full Year Outlook, Forecasting Revenue and Core Operating Profit Margin Growth

      Revenue Growth of +9.8% at Actual Exchange Rates (AER); +4.5% at Constant Exchange Rate (CER) Driven by Strong Momentum of Growth & Launch Products (+14.6% at CER) Core Operating Profit Increase of +10.1% at CER; Core OP Margin Climbs to 28.5% Reported Operating Profit +86.3% at AER Reflects Lower Impairment of Intangible Assets Compared to FY2023 Raises Adjusted Free Cash Flow Forecast Range by JPY 150.0 billion to JPY550.0 - JPY650.0 billion Announces Share Buyback of up to JPY 100.0 billion Takeda ((4502, NYSE:TAK) today announced earnings results for the third quarter of fiscal year 2024 (nine months ended December 31, 2024) showing continued advancement of its Growth &

      1/30/25 1:35:00 AM ET
      $TAK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TAK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Takeda Pharmaceutical Company Limited (Amendment)

      SC 13G/A - TAKEDA PHARMACEUTICAL CO LTD (0001395064) (Subject)

      2/6/24 9:36:34 AM ET
      $TAK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Takeda Pharmaceutical Company Limited (Amendment)

      SC 13G/A - TAKEDA PHARMACEUTICAL CO LTD (0001395064) (Subject)

      2/5/24 6:24:58 AM ET
      $TAK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Takeda Pharmaceutical Company Limited (Amendment)

      SC 13G/A - TAKEDA PHARMACEUTICAL CO LTD (0001395064) (Subject)

      2/7/23 2:10:49 PM ET
      $TAK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TAK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $TAK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $TAK
    Leadership Updates

    Live Leadership Updates

    See more
    • Takeda Pharma upgraded by Morgan Stanley

      Morgan Stanley upgraded Takeda Pharma from Equal-Weight to Overweight

      4/2/25 8:46:19 AM ET
      $TAK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Takeda Pharma upgraded by BofA Securities with a new price target

      BofA Securities upgraded Takeda Pharma from Neutral to Buy and set a new price target of $20.00

      3/16/23 7:24:52 AM ET
      $TAK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Takeda Pharma upgraded by Cowen with a new price target

      Cowen upgraded Takeda Pharma from Market Perform to Outperform and set a new price target of $24.00 from $21.00 previously

      7/19/22 7:32:25 AM ET
      $TAK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3: New insider Takeda Pharmaceutical Co Ltd claimed ownership of 840,500 shares (Amendment)

      3/A - TAKEDA PHARMACEUTICAL CO LTD (0001395064) (Reporting)

      5/9/22 6:10:39 AM ET
      $TAK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3: New insider Takeda Pharmaceutical Co Ltd claimed ownership of 500,000 shares

      3 - TAKEDA PHARMACEUTICAL CO LTD (0001395064) (Reporting)

      4/29/22 6:02:17 AM ET
      $TAK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3 filed by new insider Takeda Pharmaceutical Co Ltd

      3 - TAKEDA PHARMACEUTICAL CO LTD (0001395064) (Reporting)

      10/21/21 8:40:37 PM ET
      $TAK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vatroslav Mateljic Appointed General Manager of Takeda Canada

      Vatroslav Mateljic's innovative approach and commitment to transforming the lives of patients will strengthen Takeda's leadership position in the Canadian biopharmaceutical sectorTORONTO, Sept. 16, 2024 /CNW/ - Takeda Canada Inc. ("Takeda Canada") is pleased to announce the appointment of Vatroslav (Vatro) Mateljic as its new General Manager to lead the Canadian operations of Japan's largest pharmaceutical company. Mr. Mateljic has held a number of executive leadership roles in sales, marketing and country management over his 25-year career in the pharmaceutical industry.  Mos

      9/16/24 8:39:00 AM ET
      $TAK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Takeda Announces Candidates for Board of Directors at Upcoming Shareholders Meeting

      Takeda (TYO:4502, NYSE:TAK) today announced that its Board of Directors decided on March 26, 2024 (CET) to propose candidates for Board of Directors at the 148th Ordinary General Meeting of Shareholders to be held on June 26, 2024. Mr. Milano Furuta, currently president of the Japan Pharma Business Unit (JPBU), will succeed Mr. Constantine Saroukos as chief financial officer (CFO) effective April 1, 2024. Takeda will propose Mr. Furuta as a new candidate for board director at the Ordinary General Meeting of Shareholders. If approved by shareholders, Mr. Furuta will join the Board effective June 26, 2024. Mr. Constantine Saroukos, who expressed his intention to retire as CFO, will leave

      3/26/24 7:07:00 PM ET
      $TAK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Takeda and The New York Academy of Sciences Announce 2024 Innovators in Science Award Winners

      2024 Award Celebrates Outstanding Research in Cancer Immunology Winners Discovered Novel Connections Between the Immune System and Cancer Recipients Each Receive Unrestricted USD 200,000 Awards Takeda ((TAK) and The New York Academy of Sciences today announced the winners of the 2024 Innovators in Science Award for their excellence in, and commitment to, innovative science that has significantly advanced the field of research in cancer immunology. Each winner receives an unrestricted prize of USD 200,000. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231205723166/en/ The 2024 Senior Scientist winner is Robert D. Schre

      12/5/23 8:00:00 AM ET
      $TAK
      Biotechnology: Pharmaceutical Preparations
      Health Care